{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:02:51Z","timestamp":1790492571680,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"vor","delay-in-days":2113,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.jmoldx.2013.10.007","type":"journal-article","created":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T03:16:39Z","timestamp":1388718999000},"page":"174-179","source":"Crossref","is-referenced-by-count":110,"title":["Detection and Quantification of BCR-ABL1 Fusion Transcripts by Droplet Digital PCR"],"prefix":"10.1016","volume":"16","author":[{"given":"Lawrence J.","family":"Jennings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliann","family":"Czech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2013.10.007_bib1","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib3","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib5","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2141.1999.01749.x","article-title":"Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics","volume":"107","author":"Branford","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib6","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib7","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood-2005-11-4406","article-title":"BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML","volume":"107","author":"Press","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2353\/jmoldx.2007.060134","article-title":"Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations","volume":"9","author":"Zhang","year":"2007","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib9","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2404388","article-title":"Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia","volume":"20","author":"Branford","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib10","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib11","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1182\/blood-2010-06-291641","article-title":"Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA","volume":"116","author":"White","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib12","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","article-title":"Harmonization of molecular monitoring of CML therapy in Europe","volume":"23","author":"Muller","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib13","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib14","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.3109\/10428194.2011.580481","article-title":"Minimal residual disease: the advantages of digital over analog polymerase chain reaction","volume":"52","author":"Ross","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib15","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","author":"Cross","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib16","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib17","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib18","article-title":"Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience","author":"Benjamini","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib19","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1016\/j.ejca.2013.06.018","article-title":"Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON)","volume":"49","author":"Thielen","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib20","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib21","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.leukres.2012.02.011","article-title":"Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response","volume":"36","author":"Yhim","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib22","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2011.056853","article-title":"Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia","volume":"97","author":"Takahashi","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.cyto.2011.11.018","article-title":"Treatment with interferon alpha prior to discontinuation of imatinib in patients with chronic myeloid leukemia","volume":"57","author":"Hardan","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib24","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib25","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1158\/1078-0432.CCR-07-1112","article-title":"A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response","volume":"13","author":"Press","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib26","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood-2008-08-173674","article-title":"Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib","volume":"114","author":"Press","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib27","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","article-title":"Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations","volume":"104","author":"Branford","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib28","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4161\/chim.25400","article-title":"Detection and quantification of chimerism by droplet digital PCR","volume":"4","author":"George","year":"2013","journal-title":"Chimerism"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ymeth.2010.01.003","article-title":"Taking qPCR to a higher level: analysis of CNV reveals the power of high throughput qPCR to enhance quantitative resolution","volume":"50","author":"Weaver","year":"2010","journal-title":"Methods"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib30","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.1021\/ac202028g","article-title":"High-throughput droplet digital PCR system for absolute quantitation of DNA copy number","volume":"83","author":"Hindson","year":"2011","journal-title":"Anal Chem"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib31","doi-asserted-by":"crossref","first-page":"19920","DOI":"10.1073\/pnas.0810373105","article-title":"Noninvasive prenatal diagnosis of monogenic diseases by digital size selection and relative mutation dosage on DNA in maternal plasma","volume":"105","author":"Lun","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib32","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1373\/clinchem.2011.178939","article-title":"Digital PCR analysis of maternal plasma for noninvasive detection of sickle cell anemia","volume":"58","author":"Barrett","year":"2012","journal-title":"Clin Chem"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib33","doi-asserted-by":"crossref","first-page":"13116","DOI":"10.1073\/pnas.0705765104","article-title":"Digital PCR for the molecular detection of fetal chromosomal aneuploidy","volume":"104","author":"Lo","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib34","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/nmeth.2633","article-title":"Absolute quantification by droplet digital PCR versus analog real-time PCR","volume":"10","author":"Hindson","year":"2013","journal-title":"Nat Methods"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2144\/000114029","article-title":"Digital PCR to determine the number of transcripts from single neurons after patch-clamp recording","volume":"54","author":"Farago","year":"2013","journal-title":"Biotechniques"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib36","first-page":"444","article-title":"Quantitation of targets for PCR by use of limiting dilution","volume":"13","author":"Sykes","year":"1992","journal-title":"Biotechniques"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib37","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1021\/ac202578x","article-title":"Evaluation of a droplet digital polymerase chain reaction format for DNA copy number quantification","volume":"84","author":"Pinheiro","year":"2012","journal-title":"Anal Chem"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5858\/arpa.2011-0136-OA","article-title":"Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease","volume":"136","author":"Jennings","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib39","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jmoldx.2013.04.007","article-title":"BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"15","author":"Press","year":"2013","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib40","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1038\/bcj.2011.10","article-title":"Establishment of a standardized multiplex assay with the analytical performance required for quantitative measurement of BCR-ABL1 on the international reporting scale","volume":"1","author":"Brown","year":"2011","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib41","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3109\/10428194.2011.555569","article-title":"Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay","volume":"52","author":"Goh","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2141.2009.08071.x","article-title":"Rapid isolation of translocation breakpoints in chronic myeloid and acute promyelocytic leukaemia","volume":"149","author":"Bartley","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib43","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2009-11-255109","article-title":"In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib","volume":"116","author":"Sobrinho-Simoes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.10.007_bib44","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2353\/jmoldx.2009.080150","article-title":"Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis","volume":"11","author":"Mattarucchi","year":"2009","journal-title":"J Mol Diagn"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157813002523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157813002523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T12:42:32Z","timestamp":1576240952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157813002523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S1525157813002523"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2013.10.007","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}